Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegenerationJoanna M. Wardlaw, Martin Dichgans, Charles DeCarli et al.|The Lancet Neurology|2013Cited by 5.4k
Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trialsJonathan Emberson, Werner Hacke, Kennedy R. Lees et al.|The Lancet|2014Cited by 2.7k
The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trialStephen Phillips, Peter Sandercock, Joanna M. Wardlaw et al.|The Lancet|2012Cited by 1.2k
Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysisJoanna M. Wardlaw, Geoff Cohen, Veronica Murray et al.|The Lancet|2012Cited by 1k
Low-Dose versus Standard-Dose Intravenous Alteplase in Acute Ischemic StrokeCraig S. Anderson, John Chalmers, Thompson Robinson et al.|New England Journal of Medicine|2016Cited by 437